Videos

In this video, the second in a 6-part series, panelists discuss using monoclonal antibodies in early-line COPD treatment.

In this video, the first in a 6-part series, panelists discuss the impact of monoclonal antibodies for COPD management.

In her DERM 2025 conference interview, Martinez-Dulay highlights takeaways from her sessions on atopic dermatitis, prurigo nodularis, and lymphoma.

Bercik reviews study findings suggesting gluten restriction is not necessary for most patients with IBS, citing its apparent lack of impact on symptoms.

Cotter highlights his DERM 2025 conference presentation on navigating the diagnosis of melanoma and gene expression profiling of skin cancer.

This interview with Cotter highlights his session on the use of AI tools in the dermatology field.

Sands describes the current landscape of Crohn’s disease therapies and reviews GALAXI 2 and 3 data supporting guselkumab’s role in evolving care paradigms.

This interview with Hure covers 2 of her sessions at DERM 2025, including a discussion of microplastics and forever chemicals, as well as the skin’s microbiome.

Swanson speaks in this interview segment about her DERM 2025 session on speaking with parents and their children or teens as a clinician.

In this DERM2025 interview, Friedman highlighted some of the discussion points from his presentation on off-label strategies for therapeutic challenges.

In this interview segment with Chilukuri, he highlights takeaways from his DERM 2025 session titled ‘Advancements in Body Contouring.’

In this discussion with Chilukuri, the most notable highlights from his DERM 2025 session ‘Skincare Secrets and Quick Fixes’ were covered.

In this interview, Friedman highlights notable points from his DERM 2025 talk on managing patients with tinea.

In a new interview at the DERM2025 Conference, Boswell highlights a session on systemic drugs and another session on wart and molluscum imitators.

In a new interview at the DERM2025 Conference, Stein Gold highlighted several topical options for patients with psoriasis outside of topical steroids.

This interview with Friedman highlights the takeaways from his DERM 2025 session on managing chronic pruritus in dermatology.

Li and Shao discussed the T2D risk reduction seen over the course of the VA MOVE! lifestyle intervention program for veterans.

An analysis of data from the LUNA 3 trial indicated the comparative safety and clinical significance of the IWG criteria versus the standard platelet count threshold.

This interview segment highlights additional information on the 16-week risankizumab data from the phase 4 UnlIMMited study.

This interview with Song at DERM2025 highlights recent phase 3 data on risankizumab for genital and scalp psoriasis.

FDA approval of topical delgocitinib marks a long-awaited treatment milestone for adults with chronic hand eczema.

A review of data from an ongoing phase 3 trial indicates the potential for a generalized, prespecified fitusiran treatment for hemophilia A and B.

This episode of Lungcast features a discussion on the connection between diet, gut microbiome and lung health.

Kuter describes several studies investigating aspects of rilzabrutinib which were presented at the ISTH 2025 Congress.

Fudim discusses his experiences in prescribing GLP-1 receptor agonists, as well as his opinions regarding remote patient monitoring.

This interview with Saakshi Khattri, MD, highlights recent findings on deucravacitinib as an oral therapy for patients living with psoriatic arthritis (PsA).

Presented at ENDO 2025, crinecerfont exhibited sustained androgen reduction when combined with glucocorticoids.

Isaacs and Bellini discuss the highlights of the Endocrine Society’s annual meeting, from upcoming treatments to public education.